Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 29;295(32):10926–10939. doi: 10.1074/jbc.RA120.014103

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Darlot et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 6. — Assessment of anti-inflammatory activity of locally or systemically administered peptide in a mouse dorsal air-pouch model. A, experimental design to assess efficacy of locally administered peptide. A dorsal air pouch (a.p.) was created by subcutaneous (s.c.) injection of air on days 0 and 3. Zymosan (red) or PBS (control) was injected into the air pouch on day 6. Peptide or protein (blue) was injected into the air pouch on day 6 at the time of zymosan injection and repeated 9 h later. Air-pouch exudate was collected and analyzed on day 7 by flow cytometry (FC). Nine mice were studied in each of five study arms: PBS alone (PBS), zymosan (zymo), zymosan + scrambled peptide (SCR), zymosan + P672 (P672), and zymosan + BK1.3 (BK1.3). B–F, summary data for flow cytometry analysis for locally administered peptide. The y axis shows cell counts of total leukocytes (B), neutrophils (C), eosinophils (D), monocytes (E), and T-cells (F). The data are presented for each arm as means ± S.E. and with individual data points. Statistically significant differences (compared with zymosan) using a one-way ANOVA with Dunnett's correction for multiple comparisons, are indicated by asterisks: ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05. G, experimental design to assess the efficacy of intraperitoneally administered peptide. This is identical to that used for locally administered peptide (above) except that peptide or protein was administered intraperitoneally. Nine mice were studied in each of three study arms: zymosan + SCR (SCR), zymosan + P672 (P672), and zymosan + BK1.3 (BK1.3). H and I, summary data for flow cytometry analysis for intraperitoneally administered peptide. The y axis shows cell counts of total leukocytes (H), neutrophils (I), eosinophils (J), monocytes (K), and T-cells (L). The data are presented for each arm as means ± S.E. and with individual data points. Statistically significant differences (compared with SCR) using a one-way ANOVA with Dunnett's correction for multiple comparisons, are indicated by asterisks: ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.